Time for life science companies to step forward and adopt GxP cloud computing
This article was originally published in SRA
Developing innovative products is the raison d’être of the world’s life science companies. Traditionally, however, such companies are hesitant when it comes to adopting innovative IT solutions – such as cloud computing – for their own businesses. With the introduction of NNIT’s GxP Cloud, that is about to change, European IT service provider NNIT tells Scrip Regulatory Affairs editor Maureen Kenny.
You may also be interested in...
Bayer has failed to convince the European Medicines Agency that its marketing authorization application for finerenone should be fast-tracked through the EU's centralized review process. There were other successes, though, although Janssen is keeping us guessing over its MAA for amivantamab. These and other developments relating to the agency's accelerated assessment mechanism are logged in this latest update to the Pink Sheet's EU accelerated assessment tracker.
A number of companies have sought to convince the European Medicine Agency that their drug merits a fast-track regulatory review.
While the US and EU regulators seem less than keen on the data package offered to date on COVID-19 Vaccine AstraZeneca, Latin American countries are moving quickly to follow the UK in backing the cost-effective and more-easily deliverable option.